Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice

Background: There are no clinical studies comparing the efficacy of bevacizumab vs.aflibercept in association with folfiri in RAS mutated (RAS-M) metastatic colorectal cancer patients (mCRC) pretreated with folfox and bevacizumab. Patients and Methods: Consecutive RAS-M unresectable mCRC patients pr...

全面介紹

Na minha lista:
書目詳細資料
發表在:Front Oncol
Main Authors: Ottaiano, Alessandro, Capozzi, Monica, Tafuto, Salvatore, De Stefano, Alfonso, De Divitiis, Chiara, Romano, Carmela, Avallone, Antonio, Nasti, Guglielmo
格式: Artigo
語言:Inglês
出版: Frontiers Media S.A. 2019
主題:
Oncology
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6700318/
https://ncbi.nlm.nih.gov/pubmed/31456948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00766
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍